Complex | |
AACDB_ID: | 3122 |
PDBID: | 6WIO |
Chains: | AB_C |
Organism: | Homo sapiens |
Method: | XRD |
Resolution (Å): | 2.17 |
Reference: | 10.1371/journal.pone.0232311 |
Antibody | |
Antibody: | Secukinumab Fab |
Antibody mutation: | No |
INN (Clinical Trial): | Secukinumab(Approved) |
Antigen | |
Antigen: | Interleukin-17A |
Antigen mutation: | No |
Durg Target: | Q16552 |
Antibody
Heavy Chain: A
Mutation: NULL
>6WIO_A|Chain A|Fab Heavy chain|Homo sapiens (9606) EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC |
Light Chain: B
Mutation: NULL
>6WIO_B|Chain B|Fab Light chain|Homo sapiens (9606) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPCTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTQGTTSVTKSFNRGEC |
Antigen
Chain: C
Mutation: NULL
>6WIO_C|Chain C|Interleukin-17A|Homo sapiens (9606) MTPGKTSLVSLLLLLSLEAIVKAGITIPRNPGCPNSEDKNFPRTVMVNLNIHNRNTNTNPKRSSDYYNRSTSPWNLHRNEDPERYPSVIWEAKCRHLGCINADGNVDYHMNSVPIQQEILVLRREPPHCPNSFRLEKILVSVGCTCVTPIVHHVAHHHHHH |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
A: TRP33 TRP47 SER56 GLU57 LYS58 TYR59 TYR60 LYS65 GLY66 TYR108 ILE109 HIS110 TRP112 B: SER30 SER31 TYR33 TYR92 GLY93 SER94 SER95 PRO96 C: LEU97 ASN105 VAL106 ASP107 TYR108 HIS109 MET110 ASN111 VAL113 VAL147 THR148 PRO149 ILE150 VAL151 HIS152 HIS153 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)